ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access
Rike Syahniar1 , Maria Berlina Purba2, Heri Setiyo Bekti3 and Mardhia Mardhia4
1Department of Microbiology and Parasitology, Faculty of Medicine and Health, University of Muhammadiyah Jakarta, Jl. KH. Ahmad Dahlan, Ciputat, Cirendeu, Jakarta Selatan, Daerah Khusus Ibukota Jakarta 15419, Indonesia.
2National Quality Control Laboratory of Drug and Food, National Agency for Drug and Food Control, Jl. Percetakan Negara No.23, Jakarta Pusat, Indonesia.
3Department of Medical Laboratory Technology, Polytechnic of Health Denpasar, Jl. Sanitasi No.1, Sidakarya-Denpasar Selatan, Bali, 80224, Indonesia.
4Department of Microbiology, Faculty of Medicine, Tanjungpura University,Jl. Prof. Dr. Hadari Nawawi, Pontianak, 78124, Indonesia.
J Pure Appl Microbiol. 2020;14(4):2253-2263 | Article Number: 6476 | © The Author(s). 2020
Received: 13/06/2020 | Accepted: 08/10/2020 | Published: 10/11/2020

The coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 26 million individuals and caused 871,166 deaths globally. Various countries are racing against time to find a vaccine for controlling the rapid transmission of infection. The selection of antigen targets to trigger an immune response is crucial for vaccine development strategies. The receptor binding domain of the subunit of spike 1 protein is considered a promising vaccine candidate because of its ability to prevent attachment and infection of host cells by stimulating neutralizing antibodies. The vaccine is expected to mount a sufficient immunogenic response to eliminate the virus and store antigenic information in memory cells for long-term protection. Here, we review the ongoing clinical trials for COVID-19 vaccines and discuss the immune responses in patients administered an adequate dosage to prevent COVID-19.


COVID-19, Immune Response, SARS-CoV-2, Vaccine

Article Metrics

Article View: 447

Share This Article

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.